Company
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.
A major international trial finds dual mobility total hip replacement reduces dislocation risk after displaced femoral neck fractures compared with standard hip implants.
Hip fractures are among the most serious injuries affecting older adults, often leading to reduced independence, longer recovery periods, and increased healthcare needs. For active older patients with certain types of hip fractures, particularly displaced femoral neck fractures, total hip replacement (THR) is commonly recommended because it can help restore movement and function.
However, one of the biggest challenges after total hip replacement is joint dislocation. A new international clinical trial has found that a newer implant design called dual mobility total hip replacement (DM-THR) can significantly reduce this risk compared with traditional hip replacement systems.
The findings from the Duality trial, published in The Lancet in July 2026, provide important evidence for surgeons and healthcare systems considering the best implant options for older adults undergoing hip replacement after fracture.
The hip joint is a ball-and-socket structure that allows movement between the thigh bone and pelvis. A femoral neck fracture occurs in the upper part of the thigh bone near the hip joint. When the broken bone fragments become displaced, surgery is often required.
For healthier and more active older adults, total hip replacement may be chosen instead of partial replacement. During THR, both the damaged ball and the socket of the hip are replaced with artificial components.
Although THR can provide excellent mobility and quality of life, complications can occur. The most common early surgical problem is dislocation, where the artificial ball moves out of the socket. This may require medical procedures to reposition the joint and, in some cases, additional surgery.
Traditional hip replacements use a single articulation between the implant’s ball and socket. Dual mobility implants are designed differently.
In a dual mobility system, a smaller artificial head moves inside a larger polyethylene component, creating two points of movement. This design increases the range of motion before the joint becomes unstable, which may help prevent dislocation.
The concept was developed to improve implant stability, but until recently, strong evidence from large randomised trials was limited.
The Duality trial involved 1,600 patients aged 65 years or older who had displaced femoral neck fractures and were considered suitable candidates for total hip replacement.
The study was conducted across 44 hospitals in Sweden and the United Kingdom. Participants were randomly assigned to receive either:
Researchers followed patients for one year after surgery and measured complications, particularly hip dislocation.
The results showed a clear difference between the two groups.
Within one year:
This means patients receiving dual mobility implants had a substantially lower risk of this complication.
The researchers also found that overall surgical complications were lower among patients receiving dual mobility replacements.
The rate of any surgical complication was:
Importantly, the study found no significant differences between the two groups in:
A hip replacement dislocation can have a major impact on recovery. Even when treated without surgery, patients may experience fear of movement, reduced confidence, and limitations in daily activities.
Preventing this complication may help older adults regain independence more quickly and reduce the need for additional medical treatment.
Previous research has suggested that dislocation after hip replacement can negatively affect long-term outcomes, making implant stability an important consideration when choosing surgical options.
The findings suggest that dual mobility implants could become an important option for older adults undergoing total hip replacement after a displaced femoral neck fracture.
Although dual mobility implants can cost more than standard implants, reducing complications may lower additional healthcare costs associated with emergency treatment, repeat procedures, hospital stays, and rehabilitation.
A future economic analysis from the trial is expected to provide more information about whether the higher implant cost is balanced by improved outcomes.
While the Duality trial provides strong evidence, some limitations should be considered.
The study followed patients for one year. Although most early complications occur during this period, longer follow-up is needed to understand possible later issues such as implant wear or long-term loosening.
Additionally, surgeons used their usual surgical techniques, meaning factors such as surgical approach and implant selection may vary between hospitals.
The researchers also noted that patient-specific factors, rehabilitation approaches, and surgical details could influence outcomes.
Despite these limitations, the large size of the trial and randomised design make the findings valuable for clinical decision-making.
Hip fractures continue to represent a major health challenge among older adults worldwide. As populations age, improving surgical outcomes and reducing complications will become increasingly important.
The Duality trial provides strong evidence that dual mobility total hip replacement can reduce dislocation risk after displaced femoral neck fractures compared with conventional hip replacement.
For suitable patients undergoing total hip replacement after a hip fracture, dual mobility implants may offer a safer and more stable option.
Doctors and healthcare providers will continue to consider individual patient health, activity levels, surgical risks, and available resources when selecting the most appropriate implant.
Hailer NP, Griffin XL, Mukka S, et al. “Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.” The Lancet, published July 2, 2026.
This article is for educational and informational purposes only. It is not medical advice and should not replace consultation with a qualified healthcare professional. Treatment decisions, including the choice of hip replacement implant, should be made by patients and their doctors based on individual medical conditions, risks, and preferences.